BioLineRx Ltd.
BLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $5 | $0 | $0 |
| % Growth | 502.9% | – | – | – |
| Cost of Goods Sold | $9 | $4 | $0 | $0 |
| Gross Profit | $20 | $1 | $0 | $0 |
| % Margin | 68% | 23.1% | – | – |
| R&D Expenses | $9 | $13 | $18 | $19 |
| G&A Expenses | $18 | $17 | $5 | $4 |
| SG&A Expenses | $29 | $31 | $12 | $5 |
| Sales & Mktg Exp. | $10 | $15 | $6 | $1 |
| Other Operating Expenses | $2 | $7 | $0 | $0 |
| Operating Expenses | $40 | $51 | $29 | $25 |
| Operating Income | -$20 | -$50 | -$29 | -$25 |
| % Margin | -70.5% | -1,035.3% | – | – |
| Other Income/Exp. Net | $11 | -$11 | $4 | -$2 |
| Pre-Tax Income | -$9 | -$61 | -$25 | -$27 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$61 | -$25 | -$27 |
| % Margin | -31.9% | -1,262.8% | – | – |
| EPS | -0.12 | -0.94 | -0.48 | -0.61 |
| % Growth | 87.2% | -95.8% | 21.3% | – |
| EPS Diluted | -0.12 | -0.94 | -0.48 | -0.61 |
| Weighted Avg Shares Out | 80 | 64 | 52 | 44 |
| Weighted Avg Shares Out Dil | 80 | 64 | 52 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $1 |
| Interest Expense | $9 | $2 | $2 | $1 |
| Depreciation & Amortization | $4 | $1 | $1 | $1 |
| EBITDA | $4 | -$57 | -$29 | -$24 |
| % Margin | 13.5% | -1,189.3% | – | – |